Relypsa (RLYP) to Trade Toward Takeover Valuation After Competitor Delay - Mizuho
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
BTIG Remains Bullish on Relypsa (RLYP) Following 'Surprise' CRL for AstaZeneca's (AZN) ZS-9
May 27, 2016 8:50 AM EDTBTIG is joining in on the slew of analyst coverage for Relypsa (Nasdaq: RLYP) today.
Analyst Timothy Chiang commented today: This morning, AstraZeneca (NYSE: AZN) announced that it had received a... More
AstraZeneca's CRL on ZS-9 Reduces Near Term Commercial Risk for Veltassa and Relypsa (RLYP) - Wedbush
May 27, 2016 6:34 AM EDTWedbush analyst Liana Moussatos reiterated an Outperform rating and $51 price target on Relypsa, Inc. (NASDAQ: RLYP) after AstraZeneca announced receipt of a complete response letter (CRL) from the FDA for ZS-9 instead of approval. Moussatos notes the press release cited a failed manufacturing inspection and receipt of new data for review: The CRL refers to observations arising from a pre-approval manufacturing inspection. The FDA also acknowledged receipt of recently-submitted data which it has yet to... More
Relypsa (RLYP) Surges Higher After AstraZeneca's ZS-9 Receives CRL from FDA
May 27, 2016 6:18 AM EDTRelypsa (NASDAQ: RLYP) is surging 39% in pre-open trade after rival AstraZeneca (NYSE: AZN) received a CRL from the FDA on competing drug ZS-9, the investigational medicine being developed for the treatment of hyperkalaemia, made by ZS Pharma, a wholly-owned... More
AstraZeneca (AZN) Receives CRL on ZS-9
May 27, 2016 6:14 AM EDTAstraZeneca (NYSE: AZN) announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for sodium zirconium cyclosilicate (ZS-9), the investigational medicine being developed for the treatment of hyperkalaemia (high potassium... More
